MicroRNA-30 and 145 as Targets for the Treatment of Cardiovascular Diseases: Therapeutic Feasibility and Challenges

Author(s): Sara E.L. Tolouei, Tatiana Z. Curi, Lislaine M. Klider, Arquimedes G. Junior*

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 37 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Cardiovascular diseases (CVDs) are a group of non-communicable disorders of the heart and blood vessels. Although lifestyle changes as well as pharmacological treatments and surgical interventions are available in many countries, CVDs are still considered the number one cause of mortality worldwide. Hence, considering that most CVDs are caused by genetic and environmental imbalances, micro-RNAs (miRNAs or miRs) appear as a plausible therapeutic option for CVDs as they are able to regulate a wide number of genes due to multiple target sites in different genes. Since miRNA-30 and -145 have been shown to play critical roles in the cardiovascular system, acting as important regulators of many functions and biological processes, this review focuses on summarizing recent findings on their involvement in CVDs, mainly as targets for therapeutic intervention. Therefore, the biology, mechanisms of action and data on what has been discovered so far regarding miRNA-30 and 145 as therapeutic targets for CVDs are presented.

Keywords: Epigenetics, heart diseases, non-communicable disorders, RNA therapy, small non-coding RNAs, vascular diseases.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 37
Year: 2021
Published on: 11 December, 2020
Page: [3858 - 3870]
Pages: 13
DOI: 10.2174/1381612826666201211120822
Price: $65

Article Metrics

PDF: 263